Verition Fund Management
ACRS icon

Verition Fund Management’s Aclaris Therapeutics ACRS Stock Holding History

Verition Fund Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Buy
+20,000
New +$89.2K ﹤0.01% 1913

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Verition Fund Management's ACRS Position: Q2 2026 in Review

Verition Fund Management opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 98,000 shares worth $518K. The stake represents ﹤0.01% of the portfolio and ranks #1625 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in ACRS as recently as Q1 2025.

Verition Fund Management first reported a position in ACRS in Q2 2020 and has held it in 14 quarters since. The position peaked at $6.75M in Q2 2023. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Verition Fund Management held 98,000 shares of Aclaris Therapeutics worth $518K as of Q2 2026.
  • Aclaris Therapeutics was a new Verition Fund Management position in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1625 holding.
  • Verition Fund Management first reported a position in Aclaris Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • Verition Fund Management's Aclaris Therapeutics position peaked at $6.75M in Q2 2023.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.